ArkBio

Beyond's analysis on ArkBio

• 2026-08-13 — ArkBio secures China IND approval for long-acting antiviral AK0406, advancing influenza prophylaxis development
• 2026-07-24 — ArkBio completes dosing in Australian Phase I trial of long‑acting influenza AFC drug AK0406, moving its antiviral prophylactic program forward

Recent news mentioning ArkBio

• 2026-08-14 — ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial
• 2026-08-13 — ArkBio Announces China IND Approval for its Antiviral Drug-Fc Conjugate (AFC) Candidate AK0406 for Influenza Prophylaxis

Appears alongside

• RSV
• FDA
• China
• IND
• AFC
• AK0406

Browse the full archive →